| Bioactivity | KY-02327, a metabolically stabilized KY-02061 analog, is a potent Dishevelled (Dvl)-CXXC5 interaction inhibitor. KY-02327 shows an activating effect on the Wnt/β-catenin pathway, resulting in promotion of osteoblast differentiation[1]. | ||||||||||||
| Invitro | KY-02327 (1-10 μM; 2 days; MC3T3E1 cells, a murine pre-osteoblast cell line) increases β-catenin protein level together with Runx2 and accumulated nuclear β-catenin in a dose-dependent manner[1].KY-02327 (1-10 μM) increases the mRNA levels of osteoblast differentiation markers collagen 1a (Col1a) and osteocalcin (OCN)[1]. | ||||||||||||
| In Vivo | KY-02327 (20 mg/kg; p.o.; 5 sequential days per week for 4 weeks) successfully rescues bone loss in the ovariectomized (OVX) mouse model[1]. Animal Model: | ||||||||||||
| Name | KY-02327 | ||||||||||||
| CAS | 2093407-25-9 | ||||||||||||
| Formula | C20H27N3O4 | ||||||||||||
| Molar Mass | 373.45 | ||||||||||||
| Appearance | Solid | ||||||||||||
| Transport | Room temperature in continental US; may vary elsewhere. | ||||||||||||
| Storage |
|
||||||||||||
| Reference | [1]. Kim HY, et al. Small molecule inhibitors of the Dishevelled-CXXC5 interaction are new drug candidates for bone anabolic osteoporosis therapy. EMBO Mol Med. 2016;8(4):375-387. |
KY-02327
CAS: 2093407-25-9 F: C20H27N3O4 W: 373.45
KY-02327, a metabolically stabilized KY-02061 analog, is a potentDishevelled (Dvl)-CXXC5 interaction inhibitor. KY-02327
Sales Email：peptidedb@qq.com
This product is for research use only, not for human use. We do not sell to patients.